The table below shows Amylyx Pharmaceuticals, Inc.'s income statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
Revenue
$0.00
$87.37M
$380.79M
$22.23M
$285.00K
Cost of revenue
$0.00
$5.95M
$25.44M
$2.99M
-
Gross profit
-
-
-
-
-
R&D
$90.40M
$104.08M
$128.19M
$93.45M
$44.04M
SG&A
$62.89M
$114.33M
$188.36M
$127.13M
$38.93M
AMLX annual revenue (10-K history)
Amylyx Pharmaceuticals, Inc. reported annual revenue of $0.00 for fiscal year 2025. That is down 100.0% from $87.37M in fiscal 2024. Over the 5 fiscal years shown, annual revenue declined from $285.00K (FY 2021) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
